Collection medium for whole blood
First Claim
1. A method of preventing an initial drop in the activated clotting time measured in a recalcified activated clotting time test performed on citrated whole blood collected from a patient, the initial drop otherwise normally occurring and substantially concluding within approximately thirty minutes after drawing the blood from the patient as a result of a platelet-related procoagulant activity initiated by drawing the blood, the method comprising:
- collecting a sample of the whole blood in citrate, and approximately simultaneouslymixing an inhibitor of the initial drop with the blood sample, the inhibitor comprising one of a group consisting of a prostacyclin or imidazole.
1 Assignment
0 Petitions
Accused Products
Abstract
An inhibitor of Platelet Factor 3 activity is included in a collection medium into which a whole blood sample is a collected. The inhibitor of Platelet Factor 3 activity, it has been discovered, prevents an initial drop in the activated clotting time measured during an assay test conducted on the whole blood sample collected in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of Platelet Factor 3 activity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor of Platelet Factor 3 activity can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of Platelet Factor 3 activity.
-
Citations
16 Claims
-
1. A method of preventing an initial drop in the activated clotting time measured in a recalcified activated clotting time test performed on citrated whole blood collected from a patient, the initial drop otherwise normally occurring and substantially concluding within approximately thirty minutes after drawing the blood from the patient as a result of a platelet-related procoagulant activity initiated by drawing the blood, the method comprising:
-
collecting a sample of the whole blood in citrate, and approximately simultaneously mixing an inhibitor of the initial drop with the blood sample, the inhibitor comprising one of a group consisting of a prostacyclin or imidazole. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A method of inhibiting a platelet-related procoagulant activity in a sample of whole blood collected from a patient in a collection medium including a calcium chelating agent, which platelet-related procoagulant activity would normally develop as a result of drawing the blood sample from the patient and conclude within approximately thirty minutes after the blood sample was drawn, comprising the steps of:
mixing an inhibitor of the platelet procoagulant activity with the blood sample approximately simultaneously with collecting the sample in the collection medium, the inhibitor comprising one of the group consisting of a prostaglandin or an inhibitor of thromboxane A2 synthesis. - View Dependent Claims (8, 9, 10, 11)
-
12. A collection medium for whole blood and which is operative for inhibiting a platelet-related procoagulant activity in a sample of whole blood collected from a patient in the medium, the platelet-related procoagulant activity being one which would normally develop as a result of drawing the blood from the patient and conclude within approximately thirty minutes after the blood sample is drawn, the collection medium comprising:
-
a container in which to collect the blood sample, a calcium chelating agent contained within the container to mix with the blood sample when collected, and an inhibitor of the procoagulant activity comprising one of the group consisting of a prostaglandin or an inhibitor of thromboxane A2 synthesis. - View Dependent Claims (13, 14, 15, 16)
-
Specification